However, with the removal of sensitive cells at the initial stage of treatment, surviving tumor cells activate prosurvival pathways such as NF‐κB and HIF‐1α through epigenetic modifications (e.g., histone deacetylation), which in turn affects tumor drug resistance [205]. The gene discussed is NFKB1; the disease is neoplasm.